Summary
Health Canada has authorized RYBELSUS® as the first GLP-1 pill to reduce the risk of heart attack and stroke in adults with type 2 diabetes. While the daily pill costs approximately $2542 per patient per year, it is widely covered by provincial health plans for eligible patients who have not seen success with metformin.
In a major expansion of diabetic care, Health Canada has officially authorized RYBELSUS® (semaglutide tablets) to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with type 2 diabetes.
While RYBELSUS® has been available since 2020 to manage blood sugar, this new authorization marks it as the first and only glucagon-like peptide-1 (GLP-1) receptor agonist in pill form proven to provide direct cardiovascular protection for high-risk patients in Canada.
Beyond Blood Sugar
Cardiovascular disease remains the second-leading cause of death in Canada, and for those living with type 2 diabetes, the risk of a life-altering heart event is significantly higher. Traditionally, cardiovascular protection in the GLP-1 class was only available via weekly injections.
The authorization is based on the results of the landmark SOUL trial, which involved over 9,600 participants. The study demonstrated that a 14 mg daily dose of oral semaglutide statistically reduced the risk of major adverse cardiovascular events (MACE) by 14% over a four-year period.
“This approval marks an important milestone for type 2 diabetes patients in Canada,” says Vince Lamanna, President of Novo Nordisk Canada Inc. “RYBELSUS is the first and only approved GLP‑1 in pill form in Canada that improves glycemic control and offers cardiovascular protection.”
Coverage and Cost
Despite being a high-demand medication, RYBELSUS® is increasingly accessible across the country. The current cost is approximately $2543 per patient per year.
For most Canadians, this cost is not paid entirely out of pocket:
- Provincial Coverage: RYBELSUS® is listed on most provincial formularies under “Limited Use” criteria for patients with type 2 diabetes.
- Private Insurance: Most private employer-based insurance plans provide coverage for RYBELSUS®, though co-pays vary.
- Patent Shifts: Interestingly, as of early 2026, the patent for some semaglutide formulations has begun to expire in Canada, paving the way for future generic versions that could further lower costs.
How to Take It
Unlike its injectable counterparts, RYBELSUS® is a daily tablet. However, its effectiveness depends on strict adherence to a specific routine: it must be taken on an empty stomach in the morning with no more than 4 ounces (half a cup) of plain water, followed by a 30-minute wait before eating or drinking anything else. If you miss a dose of RYBELSUS®, skip the missed dose and go back to your regular schedule.
By offering heart protection in a simple daily pill, Health Canada’s latest authorization provides a powerful new tool for Canadians looking to manage their diabetes while proactively defending their heart health.
Subscribe to The Health Insider newsletter for more evidence-based updates on Canadian medical breakthroughs.
~ Read more from The Health Insider ~
- Is Your Gut Contributing to Social Anxiety? New Science Explains
Discover the “microbiome-first” approach to social anxiety. Learn how bacteria, diet, and new therapy techniques are changing mental healthcare. - Is an AI Redesign the Answer to Canada’s Healthcare Wait Times?Discover how a system-wide AI redesign could revolutionize Canadian healthcare productivity, diagnosis, and drug discovery according to the Fraser Institute.
- New CPR Guidelines for Canada: Why “Rescue Breaths” are Back for KidsHeart & Stroke’s updated guidelines emphasize that children need rescue breaths during CPR, as their cardiac arrests are typically oxygen-related.
- Snow & Grit: The 6 Most Demanding Winter Olympic SportsExplore the grueling world of winter athletics. From biathlon’s cardio-clash to figure skating’s grace, we rank the six hardest Olympic disciplines.
- Beyond the Diagnosis: Navigating Life with GI DisordersFrom debunking social media myths to providing peer support, learn how the GI Society helps patients manage the “new normal” of digestive health.
- Doctors Warn Canadians are “5x More Likely” to Experience Harm from AI Health AdviceSummaryA Feb 2026 CMA report warns that following health advice from AI leads to 5x more medical harm. While Canadians use these tools for speed, 77% are worried about U.S. misinformation. Doctors are calling for urgent regulation to ensure AI enhances care rather than endangering patients. A new report released today by the Canadian Medical…
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
